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Key Points
•CD30 CAR T-cell ther-
apy promoted a pro-
longed remission in
a patient with multiply
relapsed EATL.
Introduction
Enteropathy-associated T-cell lymphoma (EATL) is a rare lymphoma arising in the setting of celiac
disease.1 Multiagent anthracycline-based chemotherapy alone is associated with poor long-term
outcomes with a median overall survival of only 7 months.2,3 In patients who achieve a response to first-
line therapy and are eligible for autologous stem cell transplantation (SCT), 5-year median overall survival
can be improved to 50% to 60%.3-5 Because ;50% of patients with EATL express the CD30 antigen,
targeted therapy with brentuximab vedotin has been explored with promising outcomes.6,7 We have
recently completed a phase 1/2 study showing safety and efficacy of chimeric antigen receptor (CAR)–
modified T cells targeting the CD30 molecule (CD30 CAR T cells) in CD301 Hodgkin lymphoma.8 Here
we describe a patient with multiply relapsed EATL after previous allogeneic SCT (allo-SCT) who
achieved a durable remission with CD30 CAR T cells.
Case description
A 69-year-old male with a history of celiac disease, which was well-controlled with a gluten-free diet for
9 years, developed abdominal pain and nausea. He underwent endoscopy and biopsy, which revealed
CD301 EATL of the small bowel. A positron emission tomography/computed tomography (PET/CT)
scan at diagnosis demonstrated extensive hypermetabolic lymphadenopathy above and below the
diaphragm and extranodal disease in the small bowel. The patient was refractory to cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) and ifosfamide, carboplatin and etoposide (ICE), but
he achieved a partial response (PR) after 3 cycles of brentuximab vedotin and bendamustine and
received consolidation therapy with a nonmyeloablative allo-SCT from a matched related donor. He
received maintenance brentuximab vedotin after allo-SCT, but treatment was discontinued after 5 cycles
because of neuropathy.
Ten months after his allo-SCT, he developed a new cutaneous nodule, and a biopsy confirmed relapsed
EATL. He achieved a complete response (CR) with local radiation and brentuximab vedotin but became
refractory to brentuximab vedotin after 5 months. He subsequently was treated with 2 cycles of
romidepsin and donor lymphocyte infusion (DLI; 1.463 107 cells per kg) and achieved a short-lived PR
(,3 months). He received 2 cycles of brentuximab vedotin and a second DLI (1.0 3 108 cells per kg)
resulting in a brief CR lasting ,2 months. A new biopsy of a cervical lymph node confirmed relapsed
CD301 EATL (Figure 1A-B). Given that his disease was refractory to chemotherapy and brentuximab
vedotin, he was referred to the University of North Carolina (UNC) for treatment with CD30 CAR T cells.
Methods
This patient was treated on our phase 1b Institutional Review Board–approved clinical trial
(NCT02690545). Lymphodepleting chemotherapy consisted of bendamustine 70 mg/m2 per day and
fludarabine 30 mg/m2 per day followed by 23 108 CD30 CAR T cells per m2, manufactured at the UNC
Good Manufacturing Practice–compliant facility (IND14688).8 Disease response was determined by
PET/CT imaging at 6 weeks after CAR T-cell therapy using Lugano criteria.9 Cytokine release syndrome
(CRS) was graded according to Lee’s criteria.10 Persistence of CD30 CAR T cells in vivo was
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determined by quantitative polymerase chain reaction that used
peripheral blood samples.8 Cytokines were measured in the plasma
by Luminex assay.
Results and discussion
The CD30 CAR T-cell product characteristics were similar to those
described for CAR T cells generated from patients with Hodgkin
lymphoma.8 Specifically, after 20 days of ex vivo culture, the product
was composed of 99% T cells that expressed the CD30 CAR,
which contained both CD81 (48%) and CD41 (50%) cells, with
phenotypic characteristics of effector-memory T cells (CD45RA–
CCR7–; 75%) and a modest population of central-memory T cells
(CD45RA–CCR71; 10%). Of note, he maintained 100% donor
T-cell chimerism before CAR T-cell production, making it likely that
CAR T cells were generated from the allograft. He received 3 days
of lymphodepleting chemotherapy followed by CD30 CAR T cells
at a dose of 2 3 108 CAR T cells per m2.8
Treatment with lymphodepletion and infusion of CD30 CAR T cells
was well tolerated, with grade 3 or higher toxicities limited to
lymphopenia during the first 6 weeks, which was most likely re-
lated to lymphodepleting chemotherapy. The patient developed
grade 1 CRS on day 12, which corresponded to the peak of
CAR T-cell expansion and increased inflammatory cytokines, such
as interleukin-6 (IL-6) and interferon-g in the peripheral blood
(Figure 1C). Other CRS-related parameters included elevated
levels of C-reactive protein, ferritin, fibrinogen, and D-dimer. CRS
resolved spontaneously by day 15 and did not require specific
therapy. Although expansion of CD30 CAR T cells in this patient
was associated with an increase in the homeostatic cytokines
IL-7 and IL-15 after lymphodepletion (Figure 1D), CD30 CAR
T cells were no longer detectable by quantitative polymerase
chain reaction 3 months after infusion.8
Disease evaluation by PET/CT before receiving lymphodeple-
tion and CD30 CAR T cells showed involvement of bilateral
cervical, supraclavicular, and mediastinal nodes as well as a single
mesenteric node. All locations completely resolved 6 weeks after
CD30 CAR T-cell therapy (Figure 2). Routine imaging at 24 months
revealed continued remission, and the patient remains clinically
well on follow-up physical examinations more than 30 months
after treatment.
There is limited experience in manufacturing autologous CAR
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Figure 1. Pre–CAR-T diagnostic biopsy, CD30 CAR-T expansion, and detection of homeostatic cytokines. Hematoxylin and eosin stain (A; scale bar, 100 mm) and
CD30 antibody stain of the tumor biopsy before CAR T-cell therapy (B; scale bar, 200 mm). (C) Detection of CD30 CAR T-cell molecular signals by quantitative polymerase
chain reaction (qPCR) and of the indicated cytokines over the course of the first 6 weeks after infusion. The star indicates evaluation of the listed parameters during the CRS
event. (D) Detection of IL-2, IL-7, and IL-15 in the plasma and lymphocyte counts over the course of the first 6 weeks after infusion. ALC, absolute lymphocyte count; CRP,
C-reactive protein; DDU, D-dimer unit; IFNg, interferon-g; TNFa, tumor necrosis factor-a.
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show the feasibility of achieving therapeutic doses of CD30 CAR
T cells in a patient with EATL. To our knowledge, this is the first case
of EATL treated with CAR T-cell therapy. In this patient, who had not
achieved a durable response with 6 previous lines of therapy,
including brentuximab vedotin, allo-SCT, and multiple DLIs, we are
encouraged by both the depth and duration of response after CD30
CAR T-cell therapy. Given his previous history of allo-SCT and
100% donor chimerism at the time of CAR T-cell production, we
suspect that the CD30 CAR T cells were produced from the
allograft. The impact of previous allo-SCT on the success of CD30
CAR T-cell treatment in this patient is not known, although this
should be investigated in future studies.
There is very limited experience with CD30 CAR T-cell therapy in
treating patients with CD301 TCLs. The patient described in this
report was the only patient with EATL treated with CD30 CAR
T cells on our clinical trial. An additional adult with CD301 Sézary
syndrome was treated with the same lymphodepletion and cell
dose, achieved a PR at 6 weeks with reduction in his modified
Severity Weighted Assessment Tool (mSWAT) score from 26 to 1,
but developed a clinical relapse after 9 weeks of follow-up. Ramos
et al8 reported phase 1 dose escalation results of CD30 CAR
T cells without lymphodepletion chemotherapy, which included 2
patients with anaplastic large cell lymphoma (ALCL). The first
patient, who had cutaneous anaplastic lymphoma kinase–negative
ALCL, received a dose of 2 3 107 CAR T cells per m2 (one-log
lower than our patient) with no response. The second patient with
systemic anaplastic lymphoma kinase–positive ALCL achieved
a durable CR (9 months) after receiving 4 separate CD30 CAR
T-cell infusions at a dose of 2 3 108 CAR T cells per m2.11 A
second group, evaluating a slightly different CD30 CAR construct,
reported 1 patient with cutaneous ALCL treated with CD30 CAR
T cells at a dose of 1.5 3 107 cells per kg without previous
lymphodepletion who obtained a PR for 3 months.12
Although only ALCL and certain subsets of TCLs express CD30,
targeting this molecule with a CAR still offers numerous advan-
tages. First, fratricide is minimal, which guarantees that there will be
no deleterious effects during T-cell product manufacturing. This is in
contrast to CAR T cells targeting other T-cell lineage–associated
antigens, such as CD7, CD5, and CD4.13-15 Second, CD30 CAR
T cells have a very tolerable safety profile compared with toxicities
anticipated with CAR T cells targeting other T-cell lineage antigens.
CD30 CAR T cells have no reported deleterious effects on cellular
immunity, suggesting that the risk for opportunistic infections
should be minimal. In addition, episodes of CRS seem less severe
compared with those in which CAR T cells target other antigens
such as CD19. Finally, neurotoxicity has not been observed in
patients receiving CD30 CAR T-cell therapy.
Well-designed clinical trials are needed to expand our understand-
ing of and overcome obstacles when using CD30 CAR T cells in
TCL. The remarkable response observed in this patient should be
confirmed in a larger phase 2 trial. On the basis of experience with
CD19 CAR expansion and persistence, CAR T cells can be used as
surrogate markers for clinical outcomes. It will be important to
develop methods for increasing expansion and persistence of the
infused CD30 CAR T cells and therefore improve clinical outcomes.
In addition, each distinct TCL subset may present different
obstacles to the persistence of CAR T cells, possibly related to
the tumor environment. Finally, any effect of CD30 antigen density
on clinical responses should be investigated. To this end, UNC is
currently enrolling patients with relapsed/refractory CD301 periph-
eral TCL in a phase 2 trial that uses 2 sequential CD30 CAR T-cell
infusions at the recommended phase 2 dose of 2 3 108 CAR
T cells per m2 (NCT04083495).
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Before Infusion 6 Weeks After Infusion
Figure 2. Durable CR after CD30 CAR T-cell therapy.
Patient with multiply relapsed EATL. Before lymphodepletion
and CD30 CAR T-cell infusion, disease involved the bilateral
cervical, supraclavicular, mediastinal, hilar, and a single mesen-
teric lymph node. Six weeks after infusion, the patient achieved
a Deauville score of 1 and CR. Additional disease assessments
at 6, 12, and 24 months have continued to show CR.
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